Kanna (Sceletium tortuosum) — botanical and traditional use

A reference for the South African succulent with centuries of Khoisan use. Botany, pharmacology, product forms, and regulatory status. Educational only — not medical advice.

Explore product forms

About

Sceletium tortuosum — known in Afrikaans as kougoed ("something to chew") and in English as kanna — is a succulent native to the Karoo and Namaqualand regions of South Africa. Indigenous Khoisan and San peoples have used fermented preparations of the aerial parts for centuries, and the earliest written European records date to the 1660s. The plant contains a family of mesembrine-type alkaloids with documented serotonin-reuptake-inhibition and PDE4-inhibition activity in vitro. This site collates botanical, ethnobotanical, pharmacological, and regulatory information. It does not sell products, is not affiliated with any supplier, and is not medical advice.

Traditional preparation

The Khoisan preparation, recorded by colonial-era observers and later by ethnobotanists including Vivien Watt and Nigel Gericke, involves bruising the aerial parts of Sceletium tortuosum, sealing the material in a hide or container, and allowing it to ferment for several days. The resulting kougoed is then dried and chewed, snuffed, or smoked. Traditional use is described as calming, mildly euphoric, and sociable rather than visionary or hallucinogenic.

Fermentation is biochemically significant: it shifts the alkaloid profile, with mesembrenone proportionally decreasing relative to mesembrine. The traditional Khoisan product is therefore different in character from raw, unfermented plant material, and from modern lab-standardized extracts.

Modern extracts and Zembrin®

Most contemporary clinical and supplement-grade work uses standardized ethanolic extracts. The best-known is Zembrin®, a proprietary extract developed by HG&H Pharmaceuticals that has been studied in randomized human trials for cognition (Chiu et al., 2014) and mood. Zembrin is standardized to a defined alkaloid ratio and dosed at 25 mg per day in most published research.

Other commercial extracts vary in standardization and in alkaloid composition. The label "kanna extract" tells you very little on its own — published assays show severalfold differences in mesembrine content between products sold under the same common name. For research-grade information, look for the disclosed alkaloid profile and the assay method.

Standardization and quality markers

Useful labels disclose:

  • Total alkaloid content (commonly expressed as mesembrine equivalents, percent by mass)
  • Mesembrine : mesembrenone : Δ7-mesembrenone ratio
  • Extraction solvent (water, ethanol, supercritical CO₂)
  • Fermented vs. unfermented source material
  • Third-party identity testing (HPTLC, HPLC, or LC-MS)

Quality concerns include adulteration with other Sceletium species (notably S. emarcidum, which lacks the characteristic alkaloid profile) and microbial contamination of poorly fermented material.

Regulatory status

United States: Sceletium tortuosum is sold as a dietary ingredient. It is not a controlled substance, not FDA-evaluated for safety or efficacy, and not approved for any medical indication. Marketing as a treatment for any disease violates FDA labeling rules.

South Africa: Sceletium tortuosum is regulated under the South African National Environmental Management: Biodiversity Act, in part to protect the indigenous heritage. Commercial cultivation and export are subject to permits, and benefit-sharing agreements with the San and Khoi communities apply under access-and-benefit-sharing (ABS) frameworks.

European Union: regulatory status varies. In some member states Sceletium products fall under novel-food rules and require pre-market authorization.

Kanna product form chooser

Compare forms, delivery routes, and standardization levels. Educational only — not medical advice.

Frequently asked

Is kanna safe to combine with SSRIs?

Caution is warranted. Mesembrine and related alkaloids show serotonin-reuptake-inhibition activity in vitro. Combining kanna with prescription SSRIs, SNRIs, MAOIs, triptans, tramadol, or other serotonergic agents could theoretically increase serotonin-syndrome risk. There is no controlled human data quantifying this interaction. Discuss with your prescriber before combining.

Is kanna legal in the United States?

Yes, as a dietary ingredient. It is not a scheduled substance and is sold legally in capsules, extracts, and raw plant form. It is not FDA-approved as a drug and may not be marketed with disease claims.

Does kanna get you high?

Traditional and modern reports describe a mild, sociable, anxiolytic effect at typical doses (25–100 mg standardized extract; higher amounts of crude plant). It is generally not described as hallucinogenic or strongly intoxicating in published accounts, though individual experiences vary.

What's the difference between kanna and kratom?

They are unrelated plants with unrelated pharmacology. Kratom (Mitragyna speciosa) is a Southeast Asian tree whose alkaloids act at opioid receptors. Kanna is a South African succulent whose alkaloids act on monoamine reuptake and PDE4. Pooling them as "botanicals" obscures very different safety profiles.

Where does ethically sourced kanna come from?

Look for suppliers who can document compliance with South African access-and-benefit-sharing (ABS) requirements under the Nagoya Protocol, including benefit-sharing arrangements with the San Council and Khoi-Khoi communities. HG&H Pharmaceuticals (Zembrin) was the first to formalize such an agreement. Wild-harvested material without ABS documentation raises both legal and ethical flags.

What are typical dose ranges in published research?

Most controlled human studies with Zembrin used 25 mg per day for 8 weeks or fewer. Crude plant doses in traditional and ethnobotanical accounts range much higher because alkaloid content is lower and less consistent. We do not recommend specific doses on this site; that is a conversation with a clinician who knows you.

Want the primary literature?

Start with Smith et al. 1996 (alkaloid profile), Harvey et al. 2011 (Zembrin in vitro), and Chiu et al. 2014 (Zembrin cognition trial).

PubMed Sceletium search

Recent Posts

View all posts